WHO Prequalification Programme
WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

Tivicay 50 mg film-coated tablets [1]

Dolutegravir (as sodium salt) 50mg tablets

Tivicay 50 mg film-coated tablets was submitted by ViiV Healthcare UK Limited in 2014 to be considered for prequalification and subsequently accepted for the WHO list of prequalified medicinal products for the treatment and management of HIV/AIDS on 14 October 2014.
Information on the site(s) involved in the manufacture of the product and the API is available at the products listing information: https://extranet.who.int/prequal/medicines/ha634

The "Procedure for prequalification of pharmaceutical products[2]" defines specific evaluation mechanisms for products approved by regulatory authorities, which apply similar stringent standards for quality, safety and efficacy as those required by WHO.

The prequalification of this product by the WHO Prequalification Team: Medicines (PQTm) is based on the approval by the European Medicines Agency (EMA: https://www.ema.europa.eu/en/medicines), in line with the "Guidelines on submission of documentation for prequalification of finished pharmaceutical products approved by stringent regulatory authorities" [3].

Hence, no assessment of the data underlying this approval has been undertaken within the WHO Prequalification Team: Medicines (PQTm).

Based on the above, the WHOPAR for Tivicay 50 mg film-coated tablets refers for parts 1, 3, 4, 5, 6 and 8 to the previously issued public assessment report as follows:

WHOPAR part		**Reference[4]**
Part 1	Summary for the Public	https://www.ema.europa.eu/en/documents/assessment-report/tivicay-epar-public-assessment-report_en.pdf
Part 3	Package Leaflets	https://www.ema.europa.eu/en/documents/product-information/tivicay-epar-product-information_en.pdf
Part 4	Summaries Product Characteristics	https://www.ema.europa.eu/en/documents/product-information/tivicay-epar-product-information_en.pdf

***** Formerly ViiV Healthcare UK Limited

[1] Trade names are not prequalified by WHO. This is the National Medicines Regulatory Authority's responsibility. Throughout this WHOPAR the proprietary name is given as an example only.

[2] https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs961-annex10-who-procedure-prequalification.pdf?sfvrsn=85029f47_2

[3] https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs986-annex5.pdf?sfvrsn=8aae767d_2

[4] https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay EMEA/H/C/002753

Part 5	Labelling	https://www.ema.europa.eu/en/documents/product-information/tivicay-epar-product-information_en.pdf
Part 6	Discussion	Tivicay-H-2753-AR-en (europa.eu)
Part 8	Steps taken following Authorization	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/002753/500171906.pdf

Parts 2 and 7 of Tivicay 50 mg film-coated tablets are included here.

Tivicay contains Dolutegravir (as sodium). Its WHO recommended use is for the treatment and management of HIV/AIDS.

Summary of Prequalification Status for Tivicay 50 mg film-coated tablets:

Initial acceptance	**Date**	**Outcome**
Status on PQ list	14 October 2014	listed
Dossier Evaluation	October 2014	MR
PQ: prequalification MR: meets requirements		

The table represents the status of relevant completed activities only.